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Abstract
Ibuprofen is a phenylpropionic acid derivative, which has analgesic, anti­
inflammatory and antipyretic actions. It is used in the management of mild to 
moderate pain, inflammatory conditions, peri-articular disorders, musculoskeletal 
disorders and joint disorders.
Tablets, like ibuprofen, can be manufactured by three different processes viz. wet 
granulation, dry granulation and direct compression. With direct compression, the 
directly compressible base, along with the active ingredient (ibuprofen) and other 
suitable excipients, can be compressed directly.
In this project, three directly compressible bases were investigated with ibuprofen. 
The three bases used were avicel pH 101, ludipress and emcompress. Experiments 
were done using three different concentrations (40, 50 and 60%) of the directly 
compressible base. At each concentration, tablets were compressed to three different 
hardness levels (3-5, 6-8 and 7-9 kg). Therefore a total of twenty-seven formulations 
were compressed and the tablets from each formulation were evaluated for uniformity 
of weight, disintegration and friability.
The angle of repose test for powder flow showed excellent results. Emcompress 
showed the most superior flow, followed by ludipress and then avicel.
The disintegration for avicel was excellent, with all nine formulations of avicel 
disintegrating almost immediately. Since emcompress is insoluble in water, all nine 
formulations failed disintegration. Only two formulations of ludipress, at a 60% 
concentration, passed disintegration. However with the addition of the disintegrant, 
explotab, both emcompress and ludipress passed disintegration. Therefore a 
disintegrant will have to be added to an emcompress or ludipress formulation, the 
percentage of which, will determine the rate at which tablets disintegrate.
The friability of ludipress and emcompress were excellent with all formulations 
passing. With avicel, only six formulations passed friability. The three formulations 
that failed were at a higher hardness level.
Overall, the best results were obtained with avicel. Such tablets demonstrated rapid 
disintegration. This would be ideal for an ibuprofen formulation where a rapid 
response is needed.
iv
Acknowledgements
Dr Gareth Lowndes
Pharma Q
- For his supervision and motivation throughout my 
project.
- For the supply of all raw materials required.
- For her support, encouragement and typing expertise.Mariam Vawda
Table of contents
Declaration
Page
ii
Dedication iii
Abstract iv
Acknowledgements V
Table of contents vi
List of figures ix
List of tables X
1. Introduction 1
1.1 Background 1
1.2 Manufacturing processes 2
1.2.1 Wet granulation 2
1.2.2 Dry granulation 2
1.2.3 Direct compression 2
1.3 Excipients 5
1.3.1 Lubricants 5
1.3.2 Disintegrants 5
1.3.3 Fillers or diluents 5
1.4.1 Microcrystalline Cellulose (Avicel PHI01®) 7
1.4.2 Lactose (Ludipress®) 8
1.4.3 Dibasic Calcium Phosphate (Emcompress®) 8
VI
2. Experimentation 9
2.1 Introduction 9
2.2 Samples 10
2.3 Methods 11
2.3.1 Uniformity of weight 11
2.3.2 Hardness 11
2.3.3 Friability 11
2.3.4 Disintegration 11
2.3.5 Flow properties 12
3. Results 14
3.1 Avicel pH 101 14
3.2 Ludipress 14
3.3 Emcompress 15
3.4 Disintegration 15
3.4.1 Acidic medium 16
3.4.2 Addition of a disintegrant 16
3.5 Powder flow 16
4. Discussion 17
4.1 Introduction 17
4.2 Avicel pH 101 17
4.3 Ludipress 19
4.4 Emcompress 21
4.5 Powder flow 22
vii
5. Conclusion 24
Appendix -  Ethics clearance 26
6. References 28
viii
List of figures
Figure Page
1.1 Schematic drawings of the three different methods 
in which tablets can be manufactured 4
2.1 Friabilator 12
2.2 Disintegration apparatus 12
2.3 The poured angle on repose 13
4.1 Disintegration for avicel 18
4.2 Friability for avicel 19
4.3 Disintegration for ludipress 20
4.4 Friability for ludipress 20
4.5 Friability for emcompress 21
4.6 Micrograph for emcompress 22
4.7 Micrograph for ludipress 23
4.8 Micrograph for avicel 23
5.1 Disintegration for formulations 4, 5, 29, 30, 31 24
5.2 Friability for formulations 4, 5, 29, 30, 31 24
IX
List of tables
Table Page
1.1 Comparative properties of some fillers 6
2.1 Formulations at concentrations 40,50 and 60% 9
2.2 Numerical allocation for the formulations 10
2.3 List of excipients with their ingredients 10
3.1 Results for avicel 14
3.2 Results for ludipress 14
3.3 Results for emcompress 15
3.4 Powder flow 16
4.1 Summary of results 17
X
Introduction
1.1 Background
Solid oral dosage forms are drug delivery systems presented as solid-dose units 
readily administered by mouth. The group includes tablets, capsules, unit-dose 
powders and granules. The group constitutes the most popular form of presentation 
and tablets and capsules account for the greatest number of preparations in this 
category (Banker and Rhodes, 1990). The prime reasons for this popularity includes: 
ease of accurate dosage, good physical and chemical stability, competitive unit 
production costs and an elegant distinctive appearance resulting in a high level of 
patient acceptability.
Tablets are solid medicaments, which consist of a mixture of powders, which have 
been compacted into a die to produce a single rigid body. Most formulations will be 
composed of one or more medicaments plus excipients of various types. For accurate 
reproducible dosage it is essential that each component be uniformly dispersed within 
the mixture and any tendency for component segregation be minimized. In addition, 
the processing operations demand that the mixture has certain minimum flow 
characteristics, but must be cohesive when compressed.
Pharmaceutical compressed tablets are prepared by placing an appropriate powder mix 
or granulation in a metal die on a tablet press. At the base of the die is a lower punch, 
and above the die is an upper punch. When the upper punch is forced down upon the 
powder mix (single punch press) or when the upper and lower punches squeeze 
together (rotary press) the powder mix or granulation is forced into a tablet.
A paradox in pharmaceutical tabletting is the need to manufacture a compact of 
sufficient mechanical strength to withstand the rigours of processing and packaging, 
yet capable of reproducible breakdown on administration so as to release the drug. 
Both the formulation and the method of manufacture affect the properties of a tablet, 
and between these two factors there is a high degree of interrelationship (Lieberman, 
Lachman and Schwartz, 1989). A suitable formulation is critical to the manufacture 
of satisfactory tablets. The major unit processes involved in the manufacture of tablets 
are: solid-solid mixing, solid-liquid mixing, milling, drying and compaction. The
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selection of the formulation components and equipment is done to optimize the 
efficiency of the unit processes involved.
1.2 Manufacturing processes
There are three different processes in which tablets can be manufactured:
1.2.1 Wet granulation
1.2.2 Dry granulation
1.2.3 Direct compression
1.2.1 Wet granulation
Wet granulation is the oldest method and still the most widely used process for the 
manufacture of tablets. The purpose of granulation is to enlarge the particle size of a 
powder and to obtain unifonn particles that flow readily through the tablet machine 
hopper and feed frames into the dies. The enlarged particle (granule) is prepared by 
moistening the desired powder or blended powder mixture and then passing the 
moistened mass through a screen of the mesh size that will produce the desired size 
granules. The granules are then dried before being compressed. A disadvantage with 
wet granulation is its cost. It is an expensive process because of the labour, time, 
equipment, energy and space requirements. Examples of tablets that are prepared by 
wet granulation include paracetamol, thiamine hydrochloride and aminophylline.
1.2.2 Dry granulation
In the dry granulation method, the granulation is formed not by moistening or adding 
a binding agent to the powdered drug mixture but by compacting large masses of the 
mixture and subsequently crushing and sizing these pieces into smaller granules. By 
this method, either the active ingredient or the diluent must have cohesive properties 
in order for the large masses to be formed.
1.2.3 Direct Compression
This is a process by which tablets are compressed directly from powder blends of the 
active ingredient and suitable excipients that will flow uniformly into a die cavity and 
form into a firm compact. No pretreatment of the powder blends by wet or dry 
granulation is necessary.
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Direct compression should not be conceived as a simplified modification of the 
granulation process for making tablets. It requires a new and critical approach to the 
selection of raw materials, flow properties of powder blends and effects of 
formulation variables of compressibility. During the wet granulation process the 
original properties of the raw materials are, to a great extent, completely modified.
The materials are mixed together, with a binding solution, dried, passed through a 
sieve and blended. The granulate, which is now subject to compression, is a 
combination of the raw materials. Therefore the inadequacies in the raw materials are 
covered up during the granulation process. This is not the case in direct compression. 
Therefore the properties of each and every raw material and details of how these 
materials are blended become extremely critical in the compression stage of tabletting. 
Probably, one of the least recognized advantages of direct compression is the 
optimization of tablet disintegration. Tablets prepared by direct compression have a 
faster drug release rate than tablets prepared by wet granulation (Li, 1992). Each 
primary drug particle is liberated from the tablet mass and is available for dissolution, 
resulting in a faster drug release rate. The granulation process, wherein small drug 
particles with a large surface area are 'glued' into larger agglomerates, is in direct 
opposition to the principle of increased surface area for rapid drug dissolution. 
Disintegrating agents added prior to wet granulation are known to be less effective 
than those added just prior to compression (Lieberman, Lachman and Schwartz,
1989). In direct compression all of the disintegrant is able to perform optimally, and 
when properly formulated, tablets made by direct compression should disintegrate 
rapidly to the primary particle state.
Although it is not well documented, it would seem obvious that fewer chemical 
stability problems would be encountered in tablets prepared by direct compression as 
compared to those made by the wet granulation process. The primary cause of 
instability in tablets is moisture. Moisture plays a significant role not only in drug 
stability but also in the compressibility characteristics of granulations. While some 
direct compression excipients do contain apparently high levels of moisture, this 
moisture in most cases is tightly bound either as water of hydration e.g. Lactose 
monohydrate or by hydrogen bonding to surfaces e.g. Microcrystalline cellulose and 
therefore does not degrade. (Lieberman, Lachman and Schwartz, 1989).
3
WET GRANULATION
Figure 1.1: Schematic drawings of the three different methods in which tablets can be 
manufactured (Ansel, 1981).
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1.3 Excipients
A tablet formulation contains a number of excipients in addition to the active 
ingredients. Direct compression excipients should be physiologically inert, colourless 
and tasteless. They should also be free flowing and highly compressible so as to 
produce tablets with a good hardness profile (Garr and Rubinstein, 1991). The major 
types of excipients used for a direct compression formulation are lubricants, 
disintegrants and diluents.
1.3.1 Lubricants
Lubricants are used in tablet formulations in order to ease the ejection of the tablet 
from the die, to prevent sticking of the tablets to the punches, and to prevent excess 
wear on dies and punches. Two of the factors that are critical to lubricant use are the 
particle size of the lubricant and the type and extent of mixing.
Examples include magnesium stearate and stearic acid.
1.3.2 Disintegrants
A disintegrant causes the compressed tablet to break apart when placed in an aqueous 
environment. Examples include sodium starch glycolate and croscarmellose sodium.
1.3.3 Fillers or diluents
Fillers or diluents are used to increase the bulk of the tablet so as to enable a 
formulation to become suitable for compression. In addition to lending bulk to the 
formulation, fillers are selected to improve binding and flow properties of the 
formulation. It is essential that fillers be inert and stable.
The major classes of fillers are:
Lactose e.g. fast-flo lactose®, ludipress®
Sucrose e.g. nu tab®, di-pac®, emdex®
Starch e.g. sta-Rx 1500 starch®
Cellulose e.g. avicel®, elcema ®
Dicalcium Phosphate e.g, emcompress®
Table 1.1 compares the properties of these fillers.
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Table 1.1. Comparative Properties of some Fillers
Diluents Compactibility Flowability Solubility Disintegration Hygroscopicity Lubricity Stability
Spray-dried-lactose 3 5 4 3 1 2 4
Fast-flo lactose 4 4 4 4 1 2 4
Anhydrous lactose 2 3 4 4 5 2 4
Sucrose 4 3 5 4 4 1 4
Starch 1500 3 2 2 4 3 2 4
Emcompress 3 5 0 3 1 1 5
Avicel 5 2 0 2 2 4 5
Graded on a scale from 5 (good/high) down to l(poor/low); 0 means none; (Banker and Rhodes, 1990)
The aim of this research was to evaluate three different fillers on the performance of 
ibuprofen tablets. To evaluate the three fillers, with ibuprofen, three different 
concentrations of the fillers were compressed at three different compression forces. By 
subjecting these formulations to the following tests: uniformity of weight, friability 
and disintegration; the concentration and compression force of the most ideal filler for 
ibuprofen would be determined.
The fillers chosen belong to the three major classes of direct compression fillers viz. 
cellulose, lactose and dibasic calcium phosphate.
The three fillers used were:
Microcrystalline Cellulose (avicel pH 101 ®)
Lactose (ludipress®)*
Dibasic Calcium Phosphate (emcompress*)
* Ludipress consists o f 93% lactose, 3.5% kollidon 30 and 3.5% kollidon CL.
1.4.1 Microcrystalline Cellulose (Avicel pHlOl®)
Avicel stands today as the single most important tablet excipient developed in modem 
times (Lieberman, Lachman and Schwartz, 1989). Its properties are not far from 
optimal. It is a white, insoluble, neutral, non-reactive, free-flowing, versatile filler.
It is the most compressible of all the direct compression fillers and has the highest 
dilution potential. This can be explained by the nature of the particles, which are held 
together by hydrogen bonds. Hydrogen bonds between hydrogen groups of adjacent 
cellulose molecules account exclusively for its strength and cohesiveness.
With its smaller particle size, avicel pHlOl is more compressible at a low hardness 
level compared to other grades of avicel, which have a larger particle size (Patel,
1994). It has an extremely low coefficient of friction, and therefore has no lubricant 
requirements itself. However, when more than 20% of drugs or other excipients are 
added, lubrication is necessary.
When used in concentrations of greater than 20% it is extremely effective as a 
disintegrant. This is due to its capillary action or swelling of its granules in water (Bi, 
1999). The amount of avicel used in direct compression depends on the flow and 
compression characteristics of the formulations of other ingredients. Normally the 
typical range is from 10-50%.
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Although it can be used in all methods of tabletting, it is most effectively used in 
direct compression. Because of its high chemical purity and low moisture content, 
improved chemical and colour stability of the tablets can result.
1.4.2 Lactose (Ludipress1*)
Ludipress is a formulation of auxiliaries that have been successfully used for many 
years in conventional tablet manufacture. It combines the most important functions of 
the different auxiliaries in a single product. The composition of ludipress is:
(i) Lactose acts as a carrier and filler.
(ii) Povidone (Kollidon 30®) acts as a binder.
(iii) Crospovidone (Kollidon CL®) acts as a disintegrant.
It can be combined with almost all active substances.
1.4.3 Dibasic Calcium Phosphate (Emcompress®)
Is the only widely used inorganic direct compression filler. It is relatively inexpensive 
and possesses a high degree of physical and chemical stability. It is nonhygroscopic at 
a relative humidity of up to 80%. It is a water insoluble excipient with a good fluidity 
and glidants are generally not necessary (Mulge and Turco, 1994).
It is compatible with a very broad range of active drug components. Its particles are of 
a size, shape and density, which create those flow properties demanded by modern 
tablet presses in which a maximal degree of fluidity is essential for high-speed 
compaction and tablet-to-tablet weight uniformity.
The particle size distribution is within range of a great majority of active ingredients, 
therefore ensuring uniform blending, as well as the possibility of stratification in the 
hopper of the tablet press. It is normally used at levels in the range 20-50% for both 
tablet and capsule formulations, although it has been used successfully outside this 
range.
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2. Experimentation
2.1 Introduction
The three directly compressible bases viz. avicel pHlOl, ludipress and emcompress 
were compressed at three different concentrations using three different compression 
forces. Therefore a total of 27 different formulations were tested.
Avicel is generally used at a concentration of 10-50%, ludipress at 25-75% and 
emcompress at 20-60%. Therefore the concentrations of the bases used were 40, 50 
and 60%. The hardness at which the tablets were compressed was 3-5kg, 6-8kg and 9- 
11kg. No preformulation or screening studies were performed.
Table 2.1 illustrates the formulations at concentrations 40, 50 and 60%.
Table 2.1
Concentration of D.C. Base 40% 50% 60%
Ibuprofen 200mg 200mg 200mg
Magnesium Stearate 3 mg 4mg 5mg
Directly Compressible Base* 150mg 200mg 300mg
Total 353mg 404mg SOSmg
*The amount of directly compressible base varied per formulation at concentrations 40%, 50% and 60%
Table 2.2 illustrates the numerical allocation for the 27 formulations.
Depending on the difficulty to achieve the desired concentration and hardness, each 
formulation weighed approximately 100-200g. The ibuprofen was sieved through a 
500pm mesh screen and the magnesium stearate through a 212pm mesh screen.
The ingredients for each formulation were weighed, added together and blended in a 
cube mixer for 10 minutes. The blend was then compressed on a single punch 
Manesty (type F3) tabletting machine.
9
Table 2.2 : Numerical Allocation for the Formulations
Directly Compressible Base Avicel Ludipress Emcompress
Concentration - 353mg (40%)
Hardness : 3-5kg 1 10 19
Hardness : 6-8kg 2 11 20
Hardness : 9-11kg 3 12 21
Concentration - 404mg (50%)
Hardness : 3-5kg 4 13 22
Hardness : 6-8kg 5 14 23
Hardness : 9-11kg 6 15 24
Concentration - 505mg (60%)
Hardness : 3-5kg 7 16 25
Hardness : 6-8kg 8 17 26
Hardness : 9-11kg 9 18 27
2.2 Samples
The excipients are listed in Table 2.3 with their ingredients.
Table 2.3 : Excipients Used
Sam ples C onstituents R atio (% ) A ttributes M anufacturer
Ludipress Lactose monohydrate 93.00 filler,binder BASF
Kollidon 30 3.50 binder
Kollidon CL 3.50 disintegrant
Avicel pHlOl Microcrystalline cellulose 100.00 filler,binder FMC
Emcompress Dibasic calcium phosphate 100.00 filler,binder Penwest
Magnesium Stearate 100.00 lubricant Malinckroft
Ibuprofen 100.00 active ingredient Albermarle
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2.3 Methods
The following tests were carried out on each formulation:
2.3.1 Uniformity of weight
In addition to ensuring that the desired weight had been achieved, it was essential for 
the tablets to be compressed within a defined range. Too large a variation could result 
in a too high or too low concentration of ibuprofen. The other parameters including 
the thickness and hardness of the tablet could also be affected.
The weights of 20 tablets were individually recorded. The acceptance criteria was that 
not more than 10% of the tablets tested could deviate by more than 5% of the average 
weight of the tablets.
2.3.2 Hardness
The purpose of this test was to ensure that the tablets were sufficiently hard to resist 
breaking during packaging, shipment and normal handling and yet soft enough to 
dissolve or disintegrate properly after being administered (Ansel, 1981). A Pharma 
test (PTB 311) was used to determine the crushing strength of the tablet. This test was 
carried out on 5 tablets for each formulation, to confirm that the predetermined 
hardness limits were achieved.
2.3.3 Friability
This test determined the resistance of a tablet to loss of weight and therefore indicated 
the tablets ability to withstand abrasion in handling, packaging and shipment.
For each formulation, 20 tablets were weighed before being placed in the Erweka 
friabilator (figure 2.1) with the timer set for 4 minutes. The friabilator allowed the 
tablets to roll and fall within a rotating tumbling apparatus. The tablets were weighed 
once the cycle was completed. The loss in weight and the percentage thereof was 
determined. To pass the friability the percentage loss in weight had to be less than 1%.
2.3.4 Disintegration
In order for the medicinal component of a tablet to become fully available for 
absorption from the gastrointestinal tract, the tablet must first disintegrate and 
discharge the drug to the body fluids for dissolution.
l l
The disintegration tests were performed in vitro with a Pharma test (PT2) apparatus 
(figure 2.2). This apparatus consisted of a basket-rack assembly, which contained 6 
open-ended glass tubes held vertically upon a 10-mesh screen.
During testing 6 tablets from a single formulation were placed in an aqueous medium 
at 37°C, at a frequency of between 29 and 32 cycles per minute.
Six tablets from each formulation were subjected to this test and the acceptance 
criteria were that the tablets break apart within 15 minutes.
Figure 2.1: Friabilator Figure 2.2: Disintegration Apparatus
2.3.5 Flow properties
The flow properties of the different directly compressible bases were evaluated by the 
angle of repose (0).
The value of the angle of repose for a given material is dependent upon particulate 
surface properties that will also affect flowability (Lieberman, Lachman and 
Schwartz, 1990).
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The method used was the so-called 'poured' angle method.
A powder funnel was fixed to a retort stand, so that the bottom of the orifice was 
10cm from the bench surface. The outlet was closed and the funnel filled with 5 grams 
of the directly compressible base. The contents were then allowed to pour out. The 
diameter of the cone (D) and the two opposite sides, length 1(11) and length 2 (12) 
were measured. The formula below was applied to determine the angle of repose:
Arc cos [D/Il +12]
Figure 2.3: The poured angle of repose (Wells)
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3 Results
3.1 Avicel pH 101
The results of the nine different formulations for avicel are tabulated below:
Table 3.1 : Results for Avicel
F o r m u la t io n
N u m b e r
U n ifo r m ity  
o f  W e ig h t
F r ia b ility
(%)
D is in te g r a tio n
(sec)
Concentration - 3 5 3 mg (40% )
Hardness : 3-5kg 1 passed 0.43 30
6-8kg 2 passed 0.22 36
9-11kg 3 passed failed 40
Concentration - 404m g (50% )
Hardness: 3-5kg 4 passed 0.48 15
6-8kg 5 passed 0.28 25
9-11kg 6 passed 0.60 75
Concentration - 505m g (60% )
Hardness : 3-5kg 7 passed 0.96 15
6-8kg 8 passed failed 30
9-11kg 9 passed failed 50
3.2 Ludipress
The results of the nine different formulations for ludipress are tabulated below:
Table 3.2 : Results for Ludipress
F o r m u la t io n
N u m b e r
U n ifo r m ity  
o f  W e ig h t
F r ia b ility
(%)
D is in te g r a tio n
(se c )
C on centration  - 353m g (40% )
Hardness : 3-5kg 10 passed 0.78 failed
6-8kg 11 passed 0.58 failed
9-11kg 12 passed 0.55 failed
C oncentration  - 404m g (50% )
Hardness: 3-5kg 13 passed 0.50 failed
6-8kg 14 passed 0.86 failed
9-11kg 15 passed 0.63 failed
C on centration  - 505m g (60% )
Hardness : 3-5kg 16 passed 0.92 300
6-8kg 17 passed 0.89 540
9-11kg 18 passed 0.80 failed
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Since all the results for ludipress failed at a concentration of 40% and 50%, additional 
tests were performed at a higher and lower concentration. An interval of 10% was 
chosen for the concentration, which is consistent with the interval of the three original 
concentrations. At a concentration of 70% all the parameters were met (friability: 
0.74% and disintegration: 150 seconds). At 30% the blend was sticking to the punches 
and the powder flow was poor.
3.3 Emcompress
The results of the nine different formulations for emcompress are tabulated below:
Table 3.3 : Results for Emcompress
Formulation
Number
Uniformity 
of Weight
Friability
(%)
Disintegration
(sec)
Concentration - 353m g (40% )
Hardness : 3-5kg 19 passed 0.89 failed
6-8kg 20 passed 0.95 failed
9-11kg 21 passed 0.96 failed
Concentration - 4 0 4 mg (50% )
Hardness : 3-5kg 22 passed 0.95 failed
6-8kg 23 passed 0.80 failed
9-11kg 24 passed 0.92 failed
Concentration - 505m g (60% )
Hardness : 3-5kg 25 passed 0.73 failed
6-8kg 26 passed 0.46 failed
9-11kg 27 passed 0.65 failed
All nine formulations of emcompress failed disintegration. Since emcompress is 
insoluble in water, experiments were carried out at a 20 and 30% concentration. This 
would determine if disintegration would pass at a lower concentration.
At a 20% concentration the blend was sticking to the punches and the powder flow 
was poor. At a 30% concentration all parameters were met except for the 
disintegration.
3.4 Disintegration
Of the twenty-seven formulations, fifteen failed on disintegration (tablets did not 
break apart in 15 minutes). Additional tests were carried out to determine if the
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disintegration would improve in an acidic medium or when a disintegrant was added 
to the formulation.
3.4.1 Acidic Medium
Instead of an aqueous medium, tests were done in a 0.1 M hydrochloric acid solution. 
Only avicel disintegrated (in two minutes). Both the ludipress and the emcompress did 
not disintegrate in an acidic medium.
3.4.2 Addition of a disintegrant
0.5% of the disintegrant, sodium starch glycolate (Explotab“) was added to both 
emcompress and ludipress formulations (404 mg). The results were positive with 
emcompress disintegrating in 125 seconds and ludipress in 104 seconds. The 
recommended concentration for explotab® is 2 -  8%. However at a concentration of 
0.5% both formulations passed disintegration.
3.5 Powder Flow
The flow properties of the three directly compressible bases and ibuprofen were 
evaluated by the angle of repose ( 0 ).
The results are tabulated below:
Table 3.4: Powder Flow
Angle of Repose ***Interpretation
Avicel 40% 18 excellent
Emcompress 40% 11.59 excellent
Ludipress 40% 15.94 excellent
Ibuprofen 31.20 passable
*** Relationship between the angle o f repose and powder flow
Angle of Repose Flow
less than 25 excellent
25 to 30 good
30 to 40 passable
greater than 40 very poor
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4.Discussion
4.1 Introduction
As can be seen in table 4.1 below, only eight formulations (30%) passed all three tests 
viz. uniformity of weight, friability and disintegration.
Table 4.1: Summary of Results
AVICEL LUDIPRESS EMCOMPRESS
Formulation
Number
Result Formulation
Number
Result Formulation
Number
Result
353mg (40%)
Hardness: 3-5kg 
6-8kg 
9-11kg
1 passed 10 failed 19 failed
2 passed 11 failed 20 failed
3 failed 12 failed 21 failed
404mg (50%)
Hardness: 3-5kg 
6-8kg 
9-11kg
4 passed 13 failed 22 failed
5 passed 14 failed 23 failed
6 passed 15 failed 24 failed
505mg (60%)
Hardness: 3-5kg 
6-8kg 
9-11kg
7 passed 16 passed 25 failed
8 failed 17 passed 26 failed
9 failed 18 failed 27 failed
4.2 Avicel pHlOl
Avicel produced the best results from the three directly compressible bases. Six of the 
nine formulations (67%) passed all three tests.
The disintegration results for avicel were superior when compared to ludipress and 
emcompress (figure 4.1). All nine formulations disintegrated almost immediately. 
This is due to avicel being able to maintain a porous structure in the compressed 
tablet. It shows a low interfacial tension towards aqueous liquids and enhances the 
action of capillary forces in producing a rapid penetration of water throughout the
17
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Figure 4.1 Disintegration for avicel
entire tablet matrix. The penetration of water is a prerequisite for disintegration 
because it activates the mechanisms that lead to disintegration. With avicel the water 
uptake is rapid. The penetrating water disrupts the hydrogen bond between cellulose 
and therefore causes an increase in pore volume (Pesonan, Paronen and Ketolainen, 
1989).
As can be seen in figure 4.1, as the hardness increases, so does the disintegration. An 
increase in pressure causes fragmentation and deformation of particles. The smaller 
fragments occupy void spaces and the tablet is denser. The particles are closer and 
therefore more extensive hydrogen bonding occurs. Therefore water uptake is not as 
rapid and disintegration is longer.
Only six of the nine formulations (67%) passed friability (figure 4.2) in comparison to 
ludipress and emcompress, where all formulations passed friability. However the 
actual value of the formulations that passed is lower than that of ludipress and 
emcompress. Five formulations obtained results of 0.60% or lower.
This is due to the morphology of this cellulose type. Apart from hydrogen bonding, 
mechanical interlocking occurs. The depicted tablet surface reveals partially deformed 
granules and cellulose fibres, which act as "bridges" between larger agglomerates 
(Schmidt and Rubensdorfer, 1994).
18
Percentage
I f r iabi l i ty)% )
2 4 5 6
Formulation number
Figure 4.2 Friability for avicel
Formulations 3, 8 and 9 failed friability due to capping. With avicel, robust compacts 
are formed at comparatively low compaction pressures due to interparticulate 
bonding. Therefore higher compaction pressures have a negative effect on friability. 
When comparing the disintegration and friability of the nine formulations, the best 
results are obtained at a hardness of 3-5kg irrespective of the concentration of avicel. 
The results for the six formulations that passed are similar, with formulations 4 and 5 
yielding the best results.
4.3 Ludipress
Only two of the nine formulations (22%) passed all three tests. Disintegration was a 
problem with ludipress in that seven formulations (78%) failed. Ludipress consists of 
kollidon CL (3.5%), which is a disintegrant. At low concentrations less disintegrant is 
available and the disintegration time is therefore increased.
When the disintegrant, explotab, was added to a 50% concentration of ludipress 
(404mg), it took only 104 seconds for the tablets to disintegrate (formulation 30). 
Explotab granules absorb water rapidly and swell, but do not break. The swollen 
granules remain intact, causing disintegration without bursting. It is neutral, inert and 
because the granules do not rupture, it is unreactive.
The two formulations (16 and 17) that passed disintegration were at a 60% 
concentration (figure 4.3). At this concentration, more kollidon CL is available and,
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Figure 4.3 Disintegration for ludipress
I Disintegration
therefore, these two formulations were able to disintegrate. Formulation 18 failed 
disintegration due to a higher compaction pressure. This produced a brittle fracture of 
the lactose crystals and a strong decrease of tablet porosity. Consequently water 
uptake was impeded and disintegration time increased. As the concentration of 
ludipress increased, the disintegration time decreased (Goto et al, 1999). Additional 
tests were done at a concentration of 70% ludipress (formulation 29). All three tests 
passed.
However all nine formulations passed friability. Figure 4.4 illustrates the friability for 
fomulations 16, 17, 29 and 30.
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Figure 4.4 Friability for ludipress
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Ludipress is a multipurpose excipient. It consists of kollidon 30, which is a binder. 
During compaction the lactose glass, in ludipress, undergoes plastic deformation, 
which increases the binding capacity of ludipress and therefore improves the friability 
of the formulation.
On comparing these four formulations, the best results were obtained when explotab 
was added (formulation 30). However, as the concentration of ludipress increased, the 
disintegration time decreased. The friability results for all the formulations were fairly 
constant. Therefore, ludipress should ideally be used at a concentration of at least 60% 
with ibuprofen. At lower concentrations of ludipress, a disintegrant must be added to 
the formulation.
4.4 Emcompress
All nine formulations with emcompress failed disintegration but passed friability 
(figure 4.5). Emcompress is practically insoluble in water and therefore does not 
disintegrate readily. A disintegrant must therefore be added to a formulation when 
emcompress is used. As discussed previously, experiments performed at a lower 
concentration (20% & 30%) were unsuccessful.
However, with the addition of 0.5% explotab to a 50% concentration of emcompress, 
the tablets disintegrated in 125 seconds.
Percentage
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Figure 4.5 Friability for emcompress
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Emcompress has good compression characteristics. It deforms by brittle fracture, 
when compressed; forming clean bonding surfaces which improves friability. 
Since emcompress is insoluble in water, it must be used in combination with a 
disintegrant. It appears that a higher concentration of emcompress yields superior 
results with formulation 26 showing the lowest friability.
4.5 Powder Flow
The powder flow for all three directly compressible bases were excellent (table 3.1). 
Emcompress had the best flow, with an angle of repose of 11,59; followed by 
ludipress (15,94) and then avicel (18,00).
Emcompress consists of free-flowing aggregates of small micro-crystals. 95% of the 
granules are less than 420 microns in size.
Ludipress showed good flowability due to the spherical shape of its granules and the 
lack of fibres (Schmidt and Rubensdorfer, 1994). Its larger granules have a mean 
diameter of approximately 200 microns.
Avicel had the poorest flow. This is due to its fibrous shape, which enhances internal 
bridging, resulting in poor flow. The average particle size for avicel is 50 microns. 
Figure 4.6, 4.7 and 4.8 show micrographs of emcompress, ludipress and avicel at a 
magnification of 100, 120 and 360 respectively.
Scanning Electron Microscopy(SEM)
Figure 4.6(Emcompress)
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SEM
Figure 4.7(Ludipress) 
(Schmidt and Rubensdorfer, 1994)
SEM
Figure 4.8(Avicel) 
(Wade and Welder, 1994)
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5. Conclusion
On comparing the results of the three directly compressible bases, formulations 4 and 
5 of avicel produced the best results. The addition of the disintegrant, explotab, to 
ludipress (formulation 30) and emcompress (formulation 31) produced very positive 
results. The use of ludipress at the higher concentration of 70% (formulation 29) 
proved to be effective. Figure 5.1 and 5.2 show the disintegration and friability for 
formulations 4, 5, 29, 30 and 31. (BP limits: for disintegration -  tablets must break 
apart within 900 seconds, for friability - % loss in weight must be less than 1%).
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Figure 5.1 Disintegration for formulations 4, 5, 29, 30, 31.
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Figure 5.2 Friability for formulations 4, 5, 29, 30, 31.
The two most important factors for a successful formulation are compressibility and 
fluidity. Friability is related to compressibility and flow to fluidity of a formulation. 
All three directly compressible bases showed positive results with respect to 
compressibility and fluidity.
Ibuprofen is a phenylpropionic acid derivative, which has analgesic, anti­
inflammatory and antipyretic actions. It is used in the treatment of rheumatoid arthritis 
and other musculoskeletal disorders. It has also been used in the treatment of acute 
gout (Reynolds, 1982).
With its rapid disintegration, avicel pHlOl would be ideal for an ibuprofen 
formulation where an immediate response is needed. For a slow release formulation, 
emcompress and ludipress would be more suitable. A disintegrant will most probably 
have to be added to the formulation, the percentage of which will determine the rate at 
which the tablets disintegrate.
Future objectives:
To investigate various combinations of the three directly compressible bases. Avicel 
pHlOl showed good compressibility and disintegration while emcompress and 
ludipress showed excellent flow/fluidity. The correct combination should, 
theoretically, produce an ideal directly compressible base with good compressibility, 
fluidity and disintegration characteristics.
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